Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 6/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6438024 | 0.88 | HDAC1 (0.52) | HDAC1HDAC8HDAC6PDE4BROCK2 | |
| SCHEMBL1544536 | 0.84 | HDAC1 (0.50) | HDAC1HDAC8HDAC6PDE4BALDH1A1 | |
| SCHEMBL6433569 | 0.84 | HDAC1 (0.48) | HDAC1HDAC8HDAC6PDE4BROCK2 | |
| SCHEMBL12377852 | 0.83 | HDAC1 (0.51) | HDAC1HDAC8HDAC6PDE4BROCK2 | |
| SCHEMBL3912093 | 0.82 | HDAC1 (0.50) | HDAC1HDAC8HDAC6PDE4BROCK2 | |
| SCHEMBL12522679 | 0.82 | HDAC1 (0.53) | HDAC1HDAC8HDAC6PDE4BROCK2 | |
| SCHEMBL6386434 | 0.81 | HDAC1 (0.65) | HDAC1HDAC8HDAC6PDE4BALDH1A1 | |
| SCHEMBL6439245 | 0.80 | HDAC1 (0.42) | HDAC1HDAC8HDAC6PDE4BROCK2 | |
| SCHEMBL27137907 | 0.77 | NPC1 (0.50) | PDE4BNPC1RAB9ACDK8PLAU | |
| SCHEMBL27539135 | 0.77 | LMNA (0.40) | HDAC1HDAC8HDAC6PDE4BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379522-B1 | DIHYDRO-BENZO(b)(1,4)DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I | HOFFMANN LA ROCHE (CH) | 2005-01-26 | — | — | EP | disclosed |
| EP-1379522-A1 | DIHYDRO-BENZO(b)(1,4)DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-14 | — | — | EP | disclosed |
| US-6548495-B2 | Metabotropic glutamate receptor agonist for treatment or prevention of acute and/or chronic neurological disorders | HOFFMANN-LA ROCHE INC. | 2003-04-15 | — | — | US | disclosed |
| US-20020198197-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | HOFFMANN-LA ROCHE INC. | 2002-12-26 | — | — | US | disclosed |
| WO-2002083665-A1 | DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198197-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | BDKRB1, BDKRB2, GRIN1 | HDAC1 910/4885HDAC8 2766/4885HDAC6 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.